DALLAS, April 6, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biotech company Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/SPPI
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Spectrum Pharmaceuticals Inc. (SPPI) is a commercial stage biopharmaceutical company engaged in developing and commercializing therapies with a focus primarily in the areas of hematology-oncology and urology. On December 15, 2008, Spectrum and Cell Therapeutics Inc. (CTI) partnered to form a joint venture, RIT Oncology LLC (RIT), to develop ZEVALIN ([90Y]-ibritumomab tiuxetan) in the United States. Its subsidiaries include OncoRx Pharma Private Ltd., Spectrum Pharmaceuticals GmbH, RIT Oncology LLC and Spectrum Pharma Canada. During the year ended December 31, 2008, the Company dissolved NeoJB LLC.
Message Board Search for SPPI: http://www.boardcentral.com/boards/SPPI
In the report, the analyst notes:
"Consolidated revenue of $8.6 million was comprised of product sales of $5.2 million - $5.1 million from ZEVALIN, an increase of 8.5% over third quarter 2009, and $0.1 million from FUSILEV - $1.5 million attributable to the milestone payment upon full enrollment of the apaziquone phase 3 trials, and $1.9 million attributable to the amortization of the Allergan licensing fee.
"SPPI recently announced that the first patient has been dosed in a National Cancer Institute (NCI)-sponsored phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies. The trial is designed to determine what drug doses can be safely administered together in patients, and to make dose recommendations for future clinical trials."
To read the entire report visit: http://www.beaconequity.com/i/SPPI
See what investors are saying about SPPI at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.